Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)
WithdrawnNCT05664893
Centre Antoine LacassagneHER2 Negative Breast Cancer Not Immediately Operated
Start: 2023-06-26End: 2026-03-26Updated: 2026-04-15